{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:15Z","timestamp":1784700375649,"version":"3.55.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs), particularly those targeting the programmed cell death-1 (PD-1)\/programmed cell death-ligand 1 (PD-L1) axis, have emerged as potential tools beyond cancer immunotherapy in people with HIV (PWH). In the setting of effective antiretroviral therapy (ART), chronic inflammation, T-cell exhaustion, and persistent viral reservoirs remain major obstacles to durable HIV remission or cure. Accumulating evidence suggests that ICIs may modulate these processes by reversing latency, enhancing HIV-specific immune responses, and contributing to reservoir regulation and immune restoration. In this review, we summarize current evidence on the role of ICIs in HIV infection, with a focus on reservoir regulation and immune restoration. We discuss the biological rationale for checkpoint blockade in chronic HIV infection and review available data from preclinical models, clinical studies in PWH with cancer, exploratory trials in non-cancer populations, and combination cure strategies. We also address recent findings on proviral landscape changes and key safety considerations. Overall, ICIs represent a promising but still limited component of HIV cure-oriented strategies. Their effects on reservoir dynamics and immune restoration remain heterogeneous, and further progress will require safer dosing approaches, biomarker-guided patient selection, standardized reservoir assessment, and well-designed clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1879479","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:51:53Z","timestamp":1784699513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration"],"prefix":"10.3389","volume":"17","author":[{"given":"Yixuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820480","article-title":"Persistent inflammation and non-AIDS comorbidities during ART: coming of the age of monocytes","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1038\/s41598-021-86081-w","article-title":"Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials","volume":"11","author":"Vora","year":"2021","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/737389","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncological Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx538","article-title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","volume":"28","author":"Heppt","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100247","article-title":"Brief report of anti-programmed cell death protein-1 in human immunodeficiency virus setting: relevant and breaking results in first-line NSCLC therapy","volume":"2","author":"Bertin","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00525-y","article-title":"Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer","volume":"17","author":"Lurain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13080230","article-title":"Safety and efficacy of immune checkpoint inhibitors in human immunodeficiency virus-associated cancer: a systematic scoping review","volume":"13","author":"Alatawi","year":"2025","journal-title":"Diseases"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70136","article-title":"Effective and safe use of immune checkpoint inhibitors for non-small cell lung cancer in people living with HIV","volume":"26","author":"Mispelbaum","year":"2025","journal-title":"HIV Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000957","article-title":"Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy","volume":"20","author":"Gubser","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13388","article-title":"Immune checkpoint inhibitors in infectious disease","volume":"328","author":"King","year":"2024","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.3.1979","article-title":"Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction","volume":"179","author":"D\u2019Souza","year":"2007","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001217","article-title":"Programed death-1\/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab)","volume":"30","author":"Gill","year":"2016","journal-title":"AIDS"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PloS Pathog"},{"key":"B20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052621","article-title":"HIV reservoirs and treatment strategies toward curing HIV infection","volume":"25","author":"Matsuda","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1530","article-title":"Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study","volume":"73","author":"Rasmussen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41392-024-01943-9","article-title":"Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a \u201cshock and kill\u201d strategy for ART-free virological control: a phase II single-arm study","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01952-4","article-title":"Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption","volume":"25","author":"Pereira Ribeiro","year":"2024","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"key":"B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S349099","article-title":"Transient HIV reservoirs and interleukin-6 increase after anti-programmed death-1 antibody infusion in HIV patients with lung cancer","volume":"15","author":"Peng","year":"2022","journal-title":"J Inflammation Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cells11061015","article-title":"Impact of anti PD-1 immunotherapy on HIV reservoir and anti-viral immune responses in people living with HIV and cancer","volume":"11","author":"Baron","year":"2022","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04139-y","article-title":"Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy","volume":"32","author":"Talla","year":"2026","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002919","article-title":"The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy","volume":"35","author":"Lau","year":"2021","journal-title":"AIDS"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02060","article-title":"Immunotherapy in people with HIV and cancer","volume":"10","author":"Puronen","year":"2019","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad694","article-title":"Safety and immune responses following anti-PD-1 monoclonal antibody infusions in healthy persons with human immunodeficiency virus on antiretroviral therapy","volume":"11","author":"Gay","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03993-0","article-title":"Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study","volume":"31","author":"Ramgopal","year":"2025","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.106070","article-title":"PD-1 blockade enhances functional vaccine-induced HIV-1 CD8+ T-cell responses in PWH receiving early ART","volume":"123","author":"Marin","year":"2026","journal-title":"EBioMedicine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspec"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31726","DOI":"10.1038\/s41598-025-15349-2","article-title":"Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites","volume":"15","author":"Guiraud","year":"2025","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13346","article-title":"Immune checkpoint inhibitors and infection: what is the interplay","volume":"37","author":"Papadakis","year":"2023","journal-title":"In Vivo"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1647944","article-title":"Infectious adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FAERS database","volume":"16","author":"Song","year":"2025","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/odi.12606","article-title":"Immune reconstitution inflammatory syndrome in HIV infection: taking the bad with the good","volume":"23","author":"Wong","year":"2017","journal-title":"Oral Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092227","article-title":"Immune checkpoint inhibitors in people living with HIV\/AIDS: facts and controversies","volume":"10","author":"Castelli","year":"2021","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2006816117","article-title":"Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA","volume":"117","author":"Simonetti","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01986-20","article-title":"Sequence evaluation and comparative analysis of novel assays for intact proviral HIV-1 DNA","volume":"95","author":"Gaebler","year":"2021","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00373-X","article-title":"Recommendations from the 2nd consensus workshop on analytical treatment interruption in HIV research trials","volume":"13","author":"Ndung\u2019u","year":"2026","journal-title":"Lancet HIV"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879479\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:51:54Z","timestamp":1784699514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879479\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1879479"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1879479","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1879479"}}